Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops.

van der Woning B, De Boeck G, Blanchetot C, Bobkov V, Klarenbeek A, Saunders M, Waelbroeck M, Laeremans T, Steyaert J, Hultberg A, De Haard H.

MAbs. 2016 Aug-Sep;8(6):1126-35. doi: 10.1080/19420862.2016.1189050. Epub 2016 May 21.

2.

Identification of key residues for the binding of glucagon to the N-terminal domain of its receptor: an alanine scan and modeling study.

Prévost M, Vertongen P, Waelbroeck M.

Horm Metab Res. 2012 Oct;44(11):804-9. doi: 10.1055/s-0032-1321877. Epub 2012 Aug 14.

PMID:
22893257
3.

Analysis of the glucagon receptor first extracellular loop by the substituted cysteine accessibility method.

Roberts DJ, Vertongen P, Waelbroeck M.

Peptides. 2011 Aug;32(8):1593-9. doi: 10.1016/j.peptides.2011.06.009. Epub 2011 Jun 15.

PMID:
21704096
4.

Mutational and cysteine scanning analysis of the glucagon receptor N-terminal domain.

Prévost M, Vertongen P, Raussens V, Roberts DJ, Cnudde J, Perret J, Waelbroeck M.

J Biol Chem. 2010 Oct 1;285(40):30951-8. doi: 10.1074/jbc.M110.102814. Epub 2010 Jul 20.

5.

An alternative presentation of metabolism: Enzyme-catalyzed reactions can be viewed as atoms flowing through sluice gates.

Waelbroeck M.

Biochem Mol Biol Educ. 2007 Jul;35(4):233-7. doi: 10.1002/bmb.58. Epub 2007 Jul 3.

6.

Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction.

Wuest M, Weiss A, Waelbroeck M, Braeter M, Kelly LU, Hakenberg OW, Ravens U.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Nov;374(2):87-97. Epub 2006 Oct 20.

PMID:
17053897
7.

Techniques: promiscuous Galpha proteins in basic research and drug discovery.

Kostenis E, Waelbroeck M, Milligan G.

Trends Pharmacol Sci. 2005 Nov;26(11):595-602. Epub 2005 Sep 23. Review.

PMID:
16183138
8.

Motilin and erythromycin-A share a common binding site in the third transmembrane segment of the motilin receptor.

Xu L, Depoortere I, Vertongen P, Waelbroeck M, Robberecht P, Peeters TL.

Biochem Pharmacol. 2005 Sep 15;70(6):879-87.

PMID:
16076462
9.

G protein activation by G protein coupled receptors: ternary complex formation or catalyzed reaction?

Roberts DJ, Waelbroeck M.

Biochem Pharmacol. 2004 Sep 1;68(5):799-806. Review.

PMID:
15294442
10.

Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites.

De Vriese C, Gregoire F, Lema-Kisoka R, Waelbroeck M, Robberecht P, Delporte C.

Endocrinology. 2004 Nov;145(11):4997-5005. Epub 2004 Jul 15.

PMID:
15256494
11.

Allosteric drugs acting at muscarinic acetylcholine receptors.

Waelbroeck M.

Neurochem Res. 2003 Apr;28(3-4):419-22. Review.

PMID:
12675125
12.

Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonists.

Langer I, Vertongen P, Perret J, Waelbroeck M, Robberecht P.

Neuropharmacology. 2003 Jan;44(1):125-31.

PMID:
12559130
13.
14.

A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.

Langer I, Vertongen P, Perret J, Waelbroeck M, Robberecht P.

Biochem Soc Trans. 2002 Aug;30(4):447-50. Review.

PMID:
12196112
15.

Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutations.

Waelbroeck M, Perret J, Vertongen P, Van Craenenbroeck M, Robberecht P.

Biochem Soc Trans. 2002 Aug;30(4):437-41. Review.

PMID:
12196110
16.

Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation.

Perret J, Vertongen P, Solano RM, Langer I, Cnudde J, Robberecht P, Waelbroeck M.

Br J Pharmacol. 2002 Aug;136(7):1042-8.

17.

Synthesis and affinity studies of himbacine derived muscarinic receptor antagonists.

Gao LJ, Waelbroeck M, Hofman S, Van Haver D, Milanesio M, Viterbo D, De Clercq PJ.

Bioorg Med Chem Lett. 2002 Aug 5;12(15):1909-12.

PMID:
12113806
18.

Transglutaminase-mediated polyamination of vasoactive intestinal peptide (VIP) Gln16 residue modulates VIP/PACAP receptor activity.

De Maria S, Metafora S, Metafora V, Morelli F, Robberecht P, Waelbroeck M, Stiuso P, De Rosa A, Cozzolino A, Esposito C, Facchiano A, Cartenì M.

Eur J Biochem. 2002 Jul;269(13):3211-9.

19.

VPAC(1) receptors have different agonist efficacy profiles on membrane and intact cells.

Langer I, Vertongen P, Perret J, Cnudde J, Gregoire F, De Neef P, Robberecht P, Waelbroeck M.

Cell Signal. 2002 Aug;14(8):689-94.

PMID:
12020769
20.

A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.

Langer I, Vertongen P, Perret J, Waelbroeck M, Robberecht P.

Mol Endocrinol. 2002 May;16(5):1089-96.

PMID:
11981043
21.
22.

Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16.

Langer I, Perret J, Vertongen P, Waelbroeck M, Robberecht P.

Cell Calcium. 2001 Oct;30(4):229-34.

PMID:
11587546
23.

Proline residue 280 in the second extracellular loop (EC2) of the VPAC2 receptor is essential for the receptor structure.

Vertongen P, Solano RM, Juarranz MG, Perret J, Waelbroeck M, Robberecht P.

Peptides. 2001 Sep;22(9):1363-70.

PMID:
11514016
24.

Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.

Vertongen P, Solano RM, Perret J, Langer I, Robberecht P, Waelbroeck M.

Br J Pharmacol. 2001 Aug;133(8):1249-54.

27.

Different domains of the VIP receptors modulate agonist affinity and intrinsic activity.

Juarranz MG, Van Rampelbergh J, Gourlet P, Waelbroeck M, Robberecht P.

Ann N Y Acad Sci. 2000;921:395-9. No abstract available.

PMID:
11193863
28.

Sequences (103-110) and (116-120) of the rat secretin receptor are implicated in secretin and VIP recognition.

Robberecht P, Di Paolo E, Moguilevsky N, Bollen A, Waelbroeck M.

Ann N Y Acad Sci. 2000;921:362-5. No abstract available.

PMID:
11193853
29.

Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.

Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.

Peptides. 2000 Oct;21(10):1543-9.

PMID:
11068102
30.

Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction.

Solano RM, Langer I, Perret J, Vertongen P, Juarranz MG, Robberecht P, Waelbroeck M.

J Biol Chem. 2001 Jan 12;276(2):1084-8.

31.

Evidence that the lizard helospectin peptides are O-glycosylated.

Vandermeers-Piret MC, Vandermeers A, Gourlet P, Ali MH, Waelbroeck M, Robberecht P.

Eur J Biochem. 2000 Jul;267(14):4556-60.

32.

Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.

Van Rampelbergh J, Juarranz MG, Perret J, Bondue A, Solano RM, Delporte C, De Neef P, Robberecht P, Waelbroeck M.

Br J Pharmacol. 2000 Jun;130(4):819-26.

33.

Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality.

Di Paolo E, Vilardaga JP, Petry H, Moguilevsky N, Bollen A, Robberecht P, Waelbroeck M.

Peptides. 1999;20(10):1187-93.

PMID:
10573290
34.

Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.

Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P, Waelbroeck M.

Mol Pharmacol. 1999 Dec;56(6):1280-7.

PMID:
10570056
35.

Evidence for multiple rat VPAC1 receptor states with different affinities for agonists.

Busto R, Juarranz MG, De Maria S, Robberecht P, Waelbroeck M.

Cell Signal. 1999 Sep;11(9):691-6.

PMID:
10530878
36.

Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation.

Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P, Waelbroeck M.

Eur J Biochem. 1999 Oct 1;265(1):449-56.

37.

Properties of a recombinant human secretin receptor: a comparison with the rat and rabbit receptors.

Di Paolo E, De Neef P, Moguilevsky N, Petry H, Cnudde J, Bollen A, Waelbroeck M, Robberecht P.

Pancreas. 1999 Jul;19(1):51-5.

PMID:
10416692
38.

Mutations of aromatic residues in the first transmembrane helix impair signalling by the secretin receptor.

Di Paolo E, Petry H, Moguilevsky N, Bollen A, De Neef P, Waelbroeck M, Robberecht P.

Receptors Channels. 1999;6(4):309-15.

PMID:
10412723
39.

Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.

Gourlet P, Vandermeers A, Van Rampelbergh J, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.

Ann N Y Acad Sci. 1998 Dec 11;865:247-52.

PMID:
9928018
40.

A critical view of the methods for characterization of the VIP/PACAP receptor subclasses.

Robberecht P, Waelbroeck M.

Ann N Y Acad Sci. 1998 Dec 11;865:157-63. Review.

PMID:
9928008
41.

Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.

Gourlet P, Rathé J, De Neef P, Cnudde J, Vandermeers-Piret MC, Waelbroeck M, Robberecht P.

Eur J Pharmacol. 1998 Jul 31;354(1):105-11.

PMID:
9726637
42.

Molecular cloning and in vitro properties of the recombinant rabbit secretin receptor.

Svoboda M, Tastenoy M, De Neef P, Delporte C, Waelbroeck M, Robberecht P.

Peptides. 1998;19(6):1055-62.

PMID:
9700755
43.

Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.

Gourlet P, Vandermeers-Piret MC, Rathé J, De Neef P, Cnudde J, Robberecht P, Waelbroeck M.

Eur J Pharmacol. 1998 May 1;348(1):95-9.

PMID:
9650836
44.

Contribution of the second transmembrane helix of the secretin receptor to the positioning of secretin.

Di Paolo E, De Neef P, Moguilevsky N, Petry H, Bollen A, Waelbroeck M, Robberecht P.

FEBS Lett. 1998 Mar 13;424(3):207-10.

45.

Seven helix receptors are enzymes catalysing G protein activation. What is the agonist Kact?

Waelbroeck M, Boufrahi L, Swillens S.

J Theor Biol. 1997 Jul 7;187(1):15-37.

PMID:
9236105
46.
47.

Mutational analysis of extracellular cysteine residues of rat secretin receptor shows that disulfide bridges are essential for receptor function.

Vilardaga JP, Di Paolo E, Bialek C, De Neef P, Waelbroeck M, Bollen A, Robberecht P.

Eur J Biochem. 1997 May 15;246(1):173-80.

48.

In vitro properties of a high affinity selective antagonist of the VIP1 receptor.

Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.

Peptides. 1997;18(10):1555-60.

PMID:
9437716
49.

Development of high affinity selective VIP1 receptor agonists.

Gourlet P, Vandermeers A, Vertongen P, Rathe J, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.

Peptides. 1997;18(10):1539-45.

PMID:
9437714
50.

The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.

Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Waelbroeck M, Robberecht P.

Peptides. 1997;18(3):403-8.

PMID:
9145428

Supplemental Content

Loading ...
Support Center